NDA 210933 · Alcon Labs INC
Eysuvis
Loteprednol Etabonate · Ophthalmic
NovelLast checked: Nov 19, 2026Latest source record: Oct 26, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Oct 26, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
63
16 Phase 3, 0 recruiting
FAERS reports
1,098
306 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 11, 2025.
EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. ( 1 )
Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and delay or slow healing. Corticosteroids inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. However, corticosteroids are thought to...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 26, 2020 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLabelLetterReview
1 products under this application
- EYSUVIS · LOTEPREDNOL ETABONATE 0.25% · SUSPENSION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseasePivotal-lookingCompleted
Kala Pharmaceuticals, Inc.Industry
NCT02813265 · 918 participants · Start Jun 2016 · Primary completion Oct 2017
Drug: KPI-121 0.25% Ophthalmic Suspension; Vehicle of KPI-121 0.25% Ophthalmic Suspension · For: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 60 sites in all
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye DiseasePivotal-lookingCompleted
Kala Pharmaceuticals, Inc.Industry
NCT02819284 · 909 participants · Start Jun 2016 · Primary completion Sep 2017
Drug: KPI-121 0.25% Ophthalmic Suspension; Vehicle of KPI-121 0.25% Ophthalmic Suspension · For: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Sites: Birmingham, Alabama; Chandler, Arizona; Jonesboro, Arkansas · 62 sites in all
- LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT02786901 · 600 participants · Start Jun 2016 · Primary completion Jun 13, 2017
Drug: Loteprednol Etabonate Ophthalmic Gel dosed TID; Loteprednol Etabonate Ophthalmic Gel dosed BID and 1 more · For: Cataract; Pain; Ocular Inflammation
Sites: Phoenix, Arizona; Oceanside, California; Miami, Florida · 6 sites in all
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and PainPivotal-lookingCompleted
Kala Pharmaceuticals, Inc.Industry
NCT02793817 · 520 participants · Start Jun 2016 · Primary completion Mar 2017
Drug: KPI-121 1% Ophthalmic Suspension dosed BID; Vehicle of KPI-121 Ophthalmic Suspension dosed BID · For: Post Surgical Ocular Inflammation and Pain
Sites: Chandler, Arizona; Phoenix, Arizona; Artesia, California · 35 sites in all
- Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01996839 · 514 participants · Start Dec 2013 · Primary completion May 2014
Drug: Loteprednol Etabonate Gel (BID); Loteprednol Etabonate Gel (TID) and 2 more · For: Inflammation; Pain; Cataract
Sites: Bridgewater, New Jersey
- Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01060072 · 407 participants · Start Feb 2010 · Primary completion Sep 2010
Drug: Loteprednol etabonate; Vehicle of Loteprednol Etabonate · For: Inflammation; Pain
Sites: Rochester, New York
- Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01010633 · 406 participants · Start Nov 2009 · Primary completion Jun 2010
Drug: Vehicle of Loteprednol Etabonate; Loteprednol Etabonate · For: Inflammation; Pain
Sites: Rochester, New York
- Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00645671 · 400 participants · Start Mar 2008 · Primary completion Mar 2009
Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment; Vehicle of Loteprednol Etabonate Ophthalmic Ointment · For: Ocular Inflammation
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye pain232
- eye irritation153
- off label use100
- drug ineffective95
- ocular hyperaemia75
- product dose omission issue74
- headache64
- vision blurred60
- photophobia52
- fatigue51
- ocular discomfort50
- eye swelling46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 12 |
| 2019 | 20 |
| 2020 | 31 |
| 2021 | 107 |
| 2022 | 141 |
| 2023 | 159 |
| 2024 | 185 |
| 2025 | 248 |
| 2026 | 150 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eysuvis (Loteprednol Etabonate)
2024 spending
$12.9M
Beneficiaries
14,882
25,219 claims
Per beneficiary
$867
$58.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $3,480,006 |
| 2022 | $7,384,602 |
| 2023 | $10,878,526 |
| 2024 | $12,908,618 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis.
Wu LQ, Chen X, Lou H, et al. · Curr Med Res Opin 2015 · Meta-Analysis
- Topical corticosteroids for dry eye.
Liu SH, Saldanha IJ, Abraham AG, et al. · Cochrane Database Syst Rev 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis.
Comstock TL, DeCory HH · Ocul Immunol Inflamm 2017 · Comparative Study, Multicenter Study
- Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children.
Hardas A, Singh N, Mohanty A, et al. · Eye (Lond) 2022 · Randomized Controlled Trial
- Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis.
Zhang X, Shen Z, Sun H, et al. · Int Ophthalmol 2023 · Meta-Analysis
- Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.
Oner V, Türkcü FM, Taş M, et al. · Jpn J Ophthalmol 2012 · Comparative Study, Randomized Controlled Trial
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.